OncoMatch/Clinical Trials/NCT06990321
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Is NCT06990321 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Intermediate-dose Cytarabine in Combination with Venetoclax for acute myeloid leukemia (aml).
Treatment: Intermediate-dose Cytarabine in Combination with Venetoclax — A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: induction therapy
AML patients who achieve remission with morphologic assessment of bone marrow showing no leukemic involvement after induction therapy
Lab requirements
Kidney function
Serum creatinine < 2x ULN
Liver function
Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN
Cardiac function
Ejection fraction within normal limits as determined by echocardiogram
Total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 2.5x ULN; Serum creatinine < 2x ULN; Cardiac ejection fraction within normal limits as determined by echocardiogram
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify